Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to the Chinese market with a phenomenal 14 new products approved in 2018, and their commitment to working with all stakeholders in China to deliver on their credo and their ethos of ‘patient-centricity’ in order to drive better patient outcomes.
China can really change healthcare globally through many different factors – investment, AI, cloud computing, big data and government policies. An environment is being created where innovation will improve the quality of life
